Insights in Endocervical Mucus Secretion
ConditionCervical Mucus
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age21-40
SponsorOregon Health and Science University
About this trial
Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.
Eligibility criteria
Qualifiers
Normal menstrual cycles of 25-35 days in length for at least the previous 3 cycles
BMI >18 and <35
Serum p4 >= 3 ng/ml on single sample collected between days 18-25 of self-reported menstrual cycle
Flexible schedule allowing blood draws on less than 48 hour notice
Disqualifiers
Oral contraceptive use or other hormone supplement within the preceding 2 months
Current cervical infection
Evidence of abnormal cervical cytology
Use of any IUD for contraception
Trial design
Treatments tested in this trial
- Gonadotropin Releasing Hormone Antagonists Relugolix
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Oregon Health and Science University
Lead sponsor
National Institutes of Health (NIH)
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Source ClinicalTrials.gov